Erika B Rosenzweig

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. ncbi Pulmonary arterial hypertension in children: a medical update
    Erika B Rosenzweig
    Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    Curr Opin Pediatr 20:288-93. 2008
  2. ncbi Eisenmenger's syndrome: current management
    Erika Berman Berman
    Division of Pediatric Cardiology, Department of Pediatrics, Columbia University, College of Physicians and Surgeons, New York, NY, USA
    Prog Cardiovasc Dis 45:129-38. 2002
  3. ncbi Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects
    E B Rosenzweig
    Division of Pediatric Cardiology, Columbia Presbyterian Medical Center, New York, NY, USA
    Circulation 99:1858-65. 1999
  4. ncbi Tadalafil for the treatment of pulmonary arterial hypertension
    Erika B Rosenzweig
    Columbia University Pediatric Cardiology, 3959 Broadway BH 2, North New York, New York 10032, USA
    Expert Opin Pharmacother 11:127-32. 2010
  5. ncbi Pulmonary arterial hypertension in children: a medical update
    Erika B Rosenzweig
    Department of Pediatrics, Columbia University College of Physician and Surgeons, New York, NY 10032, USA
    Indian J Pediatr 76:77-81. 2009
  6. ncbi Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension
    Erika B Rosenzweig
    Department of Pediatric Cardiology, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    J Heart Lung Transplant 27:668-74. 2008
  7. ncbi Emerging treatments for pulmonary arterial hypertension
    Erika B Rosenzweig
    Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
    Expert Opin Emerg Drugs 11:609-19. 2006
  8. ncbi Effects of long-term bosentan in children with pulmonary arterial hypertension
    Erika Berman Rosenzweig
    Division of Pediatric Cardiology, New York Presbyterian Hospital, New York, New York 10032, USA
    J Am Coll Cardiol 46:697-704. 2005
  9. ncbi Identical twins with primary pulmonary hypertension: beraprost vs epoprostenol
    Erika Berman Rosenzweig
    Children s Hospital of New York, Columbia University, College of Physicians and Surgeons, New York, NY, USA
    Chest 125:1157-60. 2004
  10. ncbi Novel therapeutics for the treatment of paediatric pulmonary arterial hypertension
    E Berman Rosenzweig
    New York Presbyterian Hospital, Division of Pediatric Cardiology, 3959 Broadway, Babies and Children s Hospital of New York, New York, NY 10032, USA
    Expert Opin Investig Drugs 10:811-23. 2001

Collaborators

Detail Information

Publications21

  1. ncbi Pulmonary arterial hypertension in children: a medical update
    Erika B Rosenzweig
    Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    Curr Opin Pediatr 20:288-93. 2008
    ....
  2. ncbi Eisenmenger's syndrome: current management
    Erika Berman Berman
    Division of Pediatric Cardiology, Department of Pediatrics, Columbia University, College of Physicians and Surgeons, New York, NY, USA
    Prog Cardiovasc Dis 45:129-38. 2002
    ..Although there is no cure for this condition at present, recent advances in management have improved the quality of life for many patients with Eisenmenger's syndrome...
  3. ncbi Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects
    E B Rosenzweig
    Division of Pediatric Cardiology, Columbia Presbyterian Medical Center, New York, NY, USA
    Circulation 99:1858-65. 1999
    ....
  4. ncbi Tadalafil for the treatment of pulmonary arterial hypertension
    Erika B Rosenzweig
    Columbia University Pediatric Cardiology, 3959 Broadway BH 2, North New York, New York 10032, USA
    Expert Opin Pharmacother 11:127-32. 2010
    ..Tadalafil, a long-acting phosphodiesterase-5 inhibitor (PDE-5) is the most recent oral agent to receive FDA approval for the treatment of pulmonary arterial hypertension (PAH)...
  5. ncbi Pulmonary arterial hypertension in children: a medical update
    Erika B Rosenzweig
    Department of Pediatrics, Columbia University College of Physician and Surgeons, New York, NY 10032, USA
    Indian J Pediatr 76:77-81. 2009
    ..A comprehensive review of the most recent literature over the past year on available and emerging novel therapies as well as an approach to target pediatric populations provides insights into the management of pediatric PAH patients...
  6. ncbi Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension
    Erika B Rosenzweig
    Department of Pediatric Cardiology, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    J Heart Lung Transplant 27:668-74. 2008
    ..We investigated the role of BMPR2 mutations on acute vasoreactivity and disease severity in IPAH/FPAH children and adults...
  7. ncbi Emerging treatments for pulmonary arterial hypertension
    Erika B Rosenzweig
    Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
    Expert Opin Emerg Drugs 11:609-19. 2006
    ..This comprehensive review of the currently available and emerging novel therapies provides insight into future management of PAH patients...
  8. ncbi Effects of long-term bosentan in children with pulmonary arterial hypertension
    Erika Berman Rosenzweig
    Division of Pediatric Cardiology, New York Presbyterian Hospital, New York, New York 10032, USA
    J Am Coll Cardiol 46:697-704. 2005
    ..This study investigated the long-term outcome of children with pulmonary arterial hypertension (PAH) treated with bosentan therapy, with or without concomitant prostanoid therapy...
  9. ncbi Identical twins with primary pulmonary hypertension: beraprost vs epoprostenol
    Erika Berman Rosenzweig
    Children s Hospital of New York, Columbia University, College of Physicians and Surgeons, New York, NY, USA
    Chest 125:1157-60. 2004
    ..The course of 12-year-old, homozygotic twins with primary pulmonary hypertension (PPH) treated with different vasoactive agents, beraprost vs epoprostenol, is described...
  10. ncbi Novel therapeutics for the treatment of paediatric pulmonary arterial hypertension
    E Berman Rosenzweig
    New York Presbyterian Hospital, Division of Pediatric Cardiology, 3959 Broadway, Babies and Children s Hospital of New York, New York, NY 10032, USA
    Expert Opin Investig Drugs 10:811-23. 2001
    ..A comprehensive review of the newer agents, with an emphasis on the pathobiology/pathophysiology of pulmonary arterial hypertension provides insight into future management of paediatric pulmonary arterial hypertension...
  11. ncbi Pulmonary arterial hypertension in children
    Erika Berman Rosenzweig
    Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York, New York 10027, USA
    Pediatr Pulmonol 38:2-22. 2004
    ..This report is a review the current state of the art for pulmonary arterial hypertension in 2004, with an emphasis on childhood pulmonary arterial hypertension and specific recommendations for current practice and future directions...
  12. ncbi Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension
    Steven M Kawut
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York City, NY, USA
    Pulm Pharmacol Ther 19:370-4. 2006
    ..We therefore hypothesized that PAH patients treated with high-affinity selective serotonin reuptake inhibitors (SSRIs) would have a reduced risk of death compared to PAH patients not treated with SSRIs...
  13. ncbi Platelet-derived growth factor is increased in pulmonary capillary hemangiomatosis
    Adel M Assaad
    Department of Pathology, Division of Surgical Pathology, 630 West 168th St, VC14 215, New York, NY 10032, USA
    Chest 131:850-5. 2007
    ..Pulmonary capillary hemangiomatosis (PCH) is a rare cause of pulmonary arterial hypertension with no effective medical therapy and a high risk of mortality. The pathogenesis of PCH is unknown...
  14. ncbi Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension
    Laura Melnick
    Division of Pediatric Cardiology, Columbia University College of Physicians and Surgeons, New York, New York, USA
    Am J Cardiol 105:1485-9. 2010
    ....
  15. ncbi von Willebrand factor independently predicts long-term survival in patients with pulmonary arterial hypertension
    Steven M Kawut
    Department of Medicine, College of Physicians and Surgeons, Joseph L Mailma School of Public Health, Columbia University, New York, NY, USA
    Chest 128:2355-62. 2005
    ....
  16. ncbi New predictors of outcome in idiopathic pulmonary arterial hypertension
    Steven M Kawut
    Department of Internal Medicine, Joseph L Mailman School of Public Health, Columbia University, 622 West 168th Street, New York, NY 10032, USA
    Am J Cardiol 95:199-203. 2005
    ..Race is identified as a new risk factor, which may be attributable to biologic or socioeconomic differences. Cardiac function and acute reactivity of the pulmonary vascular bed remain strong independent predictors of outcome...
  17. ncbi Plasma serotonin levels are normal in pulmonary arterial hypertension
    David J Lederer
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Pulm Pharmacol Ther 21:112-4. 2008
    ..Higher 5-HT levels correlated with increased six-minute walk distance (r=0.55, p=0.04). These data suggest that plasma 5-HT levels are normal in PAH. Plasma 5-HT may therefore not be a useful biomarker in this condition...
  18. ncbi Doppler-defined pulmonary hypertension and the risk of death in children with sickle cell disease followed for a mean of three years
    Margaret T Lee
    Division of Pediatric Hematology, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Br J Haematol 146:437-41. 2009
    ..PH may be a manifestation of progressive organ damage from chronic haemolysis and systemic vasculopathy that ultimately leads to early death in adulthood...
  19. ncbi Common atrium and pulmonary vascular disease
    Dina J Ferdman
    Division of Pediatric Cardiology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    Pediatr Cardiol 32:595-8. 2011
    ..Early monitoring and surgical correction, if necessary, may prevent the onset of severe pulmonary vascular disease. ..
  20. ncbi Pulmonary hypertension in children with sickle cell disease
    Warren A Zuckerman
    Columbia University Medical Center, 3959 Broadway, New York, NY 10032, USA
    Expert Rev Respir Med 5:233-43. 2011
    ..We also suggest screening, diagnostics, treatment and follow-up plans that may improve the disease burden of pulmonary hypertension in both pediatric and adult sickle cell populations...
  21. ncbi Pulmonary capillary hemangiomatosis: results of gene expression analysis
    Steven M Kawut
    Department of Medicine, College of Physicians and Surgeons, New York, NY, USA
    Chest 128:575S-5766S. 2005